Adaptimmune Therapeutics (ADAP) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist

0.579
-0.009-1.56%

Close Dec 24 13:00 ET

0.590
+0.011+1.94%

Post 17:01 ET

148.11MMarket Cap-3.47P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

European Equities Traded in the US as American Depositary Move Slightly Lower in Thursday Trading
MT NewswiresDec 19 11:08 ET
Adaptimmune Says CFO, Other C-Suite Officer to Step Down
WSJDec 19 08:23 ET
Adaptimmune: Focusing Increasing Proportion of Corporate Functions in U.S. >ADAP
Dow JonesDec 19 07:48 ET
Adaptimmune: Co-Founder, Chief Business & Strategy Officer Helen Tayton-Martin to Step Down on March 31 >ADAP
Dow JonesDec 19 07:47 ET
Express News | Adaptimmune Therapeutics PLC - Gavin Wood to Step Down as Chief Financial Officer
ReutersDec 19 07:41 ET
First Patient Treated With Adaptimmune's TECELRA(R) (Afamitresgene Autoleucel)
newsfileDec 2 16:00 ET

Comments

Jaguar8

Dec 2 18:05

🔴WATCHLIST Tuesday 12/3. NFA. Don’t open position without momentum. Use charts+indicators+order book. NO FOMO.

Note: This seems to be a long list. The rationale is that I al focused on at least 20% gains and not just after bangers. My trading style is to compound those 10-15-20-30% earnings and roll all profit rather than waiting for runners everyday. If runners appear, then I’ll grab it as well. Each has his own style earning.
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...

Trytosaveabit

Dec 2 15:03

Update

$Adaptimmune Therapeutics (ADAP.US)$ First Patient Treated With Adaptimmune's TECELRA(R) (Afamitresgene Autoleucel)
newsfile· 2 mins ago
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma

Trytosaveabit

Nov 13 16:14

Not to shabby!

$Adaptimmune Therapeutics (ADAP.US)$ Plus DATA to be presented for IGNYTE-ESO Trial of LETE-CEL in patients with SYNOVIAL SARCOMA! on 11/16/24 Saturday at CTOS annual meeting! ((((. Financial Results for the three and nine months ended September 30, 2024
● Cash / liquidity position: As of September 30, 2024, Adaptimmune had cash and cash equivalents of $116.7 million and Total Liquidity2 of $186.1 million, compared to $144.0 million and $146.9 million respectively, as of December 31...